ホーム>>Lipids>> P450>>Olivetol

Olivetol (Synonyms: 5-n-Amylresorcinol, 5-Pentylresorcinol)

カタログ番号GC30966

Olivetol は、地衣類に見られる天然のフェノールで、特定の昆虫によって生成され、カンナビノイド受容体 CB1 および CB2 の競合的阻害剤として作用します 。

Products are for research use only. Not for human use. We do not sell to patients.

Olivetol 化学構造

Cas No.: 500-66-3

サイズ 価格 在庫数 個数
100mg
$46.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Olivetol is a naturally phenol found in lichens and produced by certain insects, acting as a competitive inhibitor of the cannabinoid receptors CB1 and CB2[3]. Olivetol also inhibits CYP2C19 and CYP2D6 activity, with IC50s of 15.3 μM, 7.21 μM and Kis of 2.71 μM, 2.87 μM, respectively[1][2].

Olivetol inhibits the (S)-mephenytoin 4'-hydroxylase activity of CYP2C19 activity with an IC50 of 15.3 μM and a Ki of 2.71 μM[1]. Olivetol also inhibits AMMC O-demethylase activity of recombinant CYP2D6 with an IC50 of 7.21 μM and a Ki of 2.87 μM[2].Olivetol is a competitive inhibitor of the cannabinoid receptors CB1 and CB2[3].

[1]. Jiang R, et al. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet. 2013;28(4):332-8. [2]. Yamaori S, et al. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. [3]. James J. Carberry , et al. Composition of Olivetol and Method of Use to Reduce or Inhibit the Effects of Tetrahydrocannabinol in the Human Body. US20170143644A1

レビュー

Review for Olivetol

Average Rating: 5 ★★★★★ (Based on Reviews and 20 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Olivetol

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.